Table 5.

Ranking findings for all outcomes at drug level

Drug	SUCRA PASI 90	Rank PASI 90	SUCRA SAE	Rank SAE	SUCRA PASI 75	Rank PASI 75	SUCRA AE	Rank AE	SUCRA PGA	Rank PGA	SUCRA QoL	Rank QoL
Acitretin	9.9	19	46.9	9	26.0	15	‐	‐	‐	‐	‐	‐
Adalimumab	63.1	8	40.4	14	60.2	9	70.1	5	56.9	8	57.6	7
Alefacept	25.3	15	62.6	5	12.6	18	‐	‐	13.1	18	15.9	13
Apremilast	39.7	13	54.7	7	33.2	14	14.3	16	27.9	14	28.6	10
Brodalumab	84.3	3	39.8	15	82.1	3	46.4	9	84.0	5	52.3	8
Certolizumab	75.7	5	70.9	3	71.6	6	78.0	4	90.1	1	‐	‐
Ciclosporin	21.3	17	78.2	2	33.2	13	36.8	12	24.0	16	‐	‐
Etanercept	52.6	11	43.6	11	57.7	10	45.9	10	51.7	10	67.6	5
FAEs	21.9	16	57.7	6	11.1	19	17.8	15	15.4	17	‐	‐
Guselkumab	77.0	4	42.6	12	71.6	7	78.2	3	67.5	7	84.3	2
Infliximab	53.2	10	64.4	4	48.0	11	40.1	11	52.4	9	‐	‐
Itolizumab	56.0	9	‐	‐	71.6	8	‐	‐	29.4	13	16.0	12
Ixekizumab	94.3	1	33.7	17	91.8	1	18.1	14	85.9	3	99.2	1
Methotrexate	20.2	18	90.7	1	21.3	16	68.4	6	24.9	15	31.5	9
Placebo	2.9	20	42.0	13	0.0	20	88.0	1	0.3	19	1.2	14
Ponesimod	37.3	14	18.1	19	21.3	17	14.0	17	48.7	11	28.1	11
Secukinumab	86.5	2	29.9	18	86.7	2	36.3	13	84.4	4	‐	‐
Tildrakizumab	63.6	7	37.8	16	78.3	4	86.1	2	86.3	2	74.9	4
Tofacitinib	42.5	12	44.0	10	46.2	12	47.3	8	36.6	12	65.1	6
Ustekinumab	72.6	6	52.0	8	75.2	5	64.3	7	70.4	6	77.4	3

AE: adverse events; FAEs: fumaric acid esters; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL: specific quality of life scale; SAE: serious adverse events; SUCRA: Surface Under the Cumulative Ranking